Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Evolving concepts on human SMN pre-mRNA splicing.

Ravindra N Singh1

  • 1Department of Biomedical Sciences, College of Veterinary Medicine, Iowa State University, Ames, Iowa 50011, USA. singhr@iastate.edu

RNA Biology
|June 27, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nusinersen: the antisense oligonucleotide at the forefront of spinal muscular atrophy treatment.

RNA biology·2026
Same author

Harnessing CRISPR-dCas13Rx to identify novel antisense targets for therapeutic splicing modulation.

Molecular therapy. Nucleic acids·2026
Same author

A therapeutic antisense oligonucleotide encompassing 2'-<i>O</i>-methoxyethyl modification triggers unique perturbation of the transcriptome.

NAR molecular medicine·2026
Same author

Pre-mRNA Splicing Modulation by Antisense Oligonucleotides.

Methods in molecular biology (Clifton, N.J.)·2025
Same author

Different factors underlie mild and severe forms of spinal muscular atrophy.

Brain : a journal of neurology·2025
Same author

U1 snRNA interactions with deep intronic sequences regulate splicing of multiple exons of spinal muscular atrophy genes.

Frontiers in neuroscience·2024

Spinal muscular atrophy (SMA) is caused by SMN1 deletion and SMN2 inability to compensate. Targeting the SMN2 gene with antisense oligonucleotides (ASOs) can correct exon 7 splicing, offering a promising therapeutic strategy for SMA.

Area of Science:

  • Molecular Biology
  • Genetics
  • RNA Splicing

Background:

  • Spinal muscular atrophy (SMA) is a severe genetic disorder caused by deletion of the SMN1 gene and insufficient compensation by the SMN2 gene.
  • SMN2 exon 7 skipping, primarily due to a C6U mutation, is the molecular basis of SMA pathogenesis.
  • Understanding the regulatory mechanisms of SMN2 splicing is crucial for developing effective SMA therapies.

Purpose of the Study:

  • To elucidate the mechanisms underlying SMN2 exon 7 skipping, focusing on the roles of hnRNP A1 and novel cis-elements.
  • To identify and validate new therapeutic targets for correcting SMN2 splicing defects.
  • To evaluate the efficacy of antisense oligonucleotide (ASO)-based strategies for SMA treatment.

Main Methods:

  • Systematic mutational analysis of SMN2 exon 7 and flanking intronic sequences.

Related Experiment Videos

  • In vivo selection assays and RNA structure probing to identify functional cis-elements.
  • Antisense oligonucleotide (ASO) microwalk experiments to map optimal binding sites.
  • Assessment of SMN protein levels in SMA patient cells following ASO treatment.

    • Main Results:

    • Identification of a novel intronic splicing silencer (ISS-N1) critical for SMN2 exon 7 skipping.
    • Demonstration that ASOs targeting ISS-N1 efficiently restore SMN2 exon 7 inclusion at low nanomolar concentrations.
    • Significant restoration of SMN protein levels in SMA patient cells treated with ISS-N1-targeting ASOs.
    • Validation of bifunctional oligonucleotides for enhancing SMN2 exon 7 splicing.

    Conclusions:

    • The intronic splicing silencer ISS-N1 is a key regulator of SMN2 exon 7 splicing and a viable therapeutic target.
    • Antisense oligonucleotide (ASO)-mediated targeting of ISS-N1 offers a potent and sequence-specific strategy for SMA therapy.
    • The findings support the potential of antisense-based approaches for treating SMA by directly correcting the underlying splicing defect.